Navigation Links
U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Date:10/18/2007

F.A.C.P., Physician-in-Chief and Director of the Clinical Translational Research Division at the Translational Genomics Research Institute (TGen), Chief Scientific Officer of U.S. Oncology. "With its extensive patient screening at multiple sites, U.S. Oncology is uniquely suited to conduct such studies with a single protocol and parallel multiple regimens."

"Extensive preclinical studies demonstrated that brostallicin is synergistic with multiple agents including both bevacizumab and irinotecan," said James A. Bianco, President and CEO of CTI. "This trial is designed to rapidly follow-up that preclinical data in one consolidated phase I study, save time and expense normally associated with the start up of multiple trials, accrue eligible patients rapidly and generate data to better inform the design of future randomized phase II or III trials."

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

Brostallicin was discovered at Pharmacia and developed by Nerviano Medical Sciences (NMS) the largest pharmaceutical research and development facility in Italy and one of the largest oncology-
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mountain View, CA (PRWEB) July 29, 2014 ... officially released a new product called BNatrl Silver ... said Lis Herrey, CEO and spokesperson for BNatrl LLC. ... and your loved ones from harmful pathogens and microbes.” ... renewable energy, and clean water products, with 10 percent ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm traditionally ... care industry veteran Daryl Demonbreun and former St. Thomas ... company’s ambitious plans to grow into a full-service health ... along at a steady pace for nearly 20 years, ... says Bob Maier, founder and chief executive officer of ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According ... Market by Type (Swipe And Area), Material (Optical ... Government, Defense, Healthcare, Commercial Security and Banking & ... to 2014 - 2020", published by MarketsandMarkets, the ... $14.35 Billion by 2020, growing at a high ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical ... not only provided a comprehensive and thorough knowledge of ... drug registration but also introduced the practical operation how ... to use the Chinese trial venues to keep drug ... by step. , The audiences of this guidebook are ...
(Date:7/29/2014)... There is controversy over how best to treat patients ... one wait until the cancer comes back or provide ... Now, a new study from Thomas Jefferson ... doctors and patients make a more informed decision. , ... says first author Robert Den, M.D., Assistant Professor of ...
Breaking Medicine News(10 mins):Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2
... LANSING, Mich., Dec. 30 Neogen Corporation,(Nasdaq: NEOG ) announces the ... Quarter Results Webcast, When: Tuesday, January 6, 2009 ... How: Live over the Internet -- Simply log on to ... above., Contact: Terry Maynard of Neogen ...
... for Nearly 20% of 45 plus PopulationCHICAGO, Dec. 30 ... be your health. According to a recent AARP ... are suffering health problems due to financial stress. ... many Americans are facing because of the current economic ...
... - Stubbing Out Your 5 a Day Habit ... , Leading Child Trust Fund provider, ... decide,to give up smoking as their New Year,s resolution to ... futures. , According to figures from ...
... New Year,s resolutions often include being more careful, ... behavior, such as drug use. But new research ... seekers by psychologists--face an uphill battle in keeping ... their brains process dopamine. The research reveals that ...
... Committee for Quality,Assurance and the American Diabetes Association ... Barnett, M.D., Mirela Sturzu,M.D., Rudolf Teschan, M.D., and ... Recognition Program for providing quality care to,patients with ... and Zaki practice at the Aurora Health Center, ...
... CORONA, Calif., Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... and specialty branded pharmaceuticals,today announced that its subsidiary, ... United States Food and Drug Administration on its,Abbreviated ... estradiol tablets USP, 0.15 mg / 0.02 mg. ...
Cached Medicine News:Health News:Economic Stress Taking Toll on Peoples' Health 2Health News:Urging New Year Quitters to Invest in Their Family's Futures 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Aurora Physicians Receive National Recognition for Quality Diabetes Care 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2
(Date:7/29/2014)... 2014   Health 2.0 announces Bernard Tyson ... physicians Eric Topol , Patrick Soon-Shiong , and ... 2.0 8th Annual Fall Conference this coming Sept. 21-24 ... Health 2.0 is set to host the very first Wearable ... on Consumer Tech & Wearables: Powering Healthy Lifestyles. ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
... NEAR-SkinT™ Incise Drapes have aggressive ... permeability for extended adhesion. It's made ... for unsurpassed conformability with allow-glare matte ... identification. , ,Available sterile in ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The HYBrite Hybridization System - the hands-free ... Procedures. Now performing fluorescent in situ hybridization ... ever before. HYBrite is the first rapid, ... FISH procedures. Now you can have a ...
... CELL-DYN 4000 uses the power of ... parameters to the hematology laboratory. Fluorescent ... random-access reticulocyte results. Fluorescent DNA staining ... accurate white blood cell values and ...
Medicine Products: